MorphoSys Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Martinsried Germany (1992)

Organization Overview

First Clinical Trial
2009
NCT01023256
First Marketed Drug
2020
tafasitamab
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Morphosys | MorphoSys AG | MORPHOSYS US INC